In Vivo Vulnerabilities to GPX4 and HDAC Inhibitors in Drug-Persistent Versus Drug-Resistant BRAFV600E Lung Adenocarcinoma
Marie-Julie Nokin,Elodie Darbo,Elodie Richard, Sonia San Jose, Sergio de Hita,Valerie Prouzet-Mauleon,Beatrice Turcq, Laura Gerardelli,Rebekah Crake,Valerie Velasco,Benjamin Koopmansch,Frederic Lambert,Jenny Y. Xue,Ben Sang,Julie Horne,Eric Ziemons,Alberto Villanueva,Arnaud Blomme,Michael Herfs,Didier Cataldo,Olivier Calvayrac,Paolo Porporato,Ernest Nadal,Piro Lito,Pasi A. Janne,Biagio Ricciuti,Mark M. Awad,Chiara Ambrogio,David Santamaria, Bolero Consortium CELL REPORTS MEDICINE（2024）
关键词
lung adenocarcinoma,BRAF oncogene,targeted therapy,persister cells,ferroptosis,GPX4 inhibition,HDAC inhibition
AI 理解论文
溯源树
样例
